DNMT3B siRNA (Mouse)
Cat# MBS8221677-30nmol
Size : 30nmol
Brand : MyBiosource
DNMT3B siRNA – DNA (Cytosine-5)-Methyltransferase 3b Isoform 2 (Mouse)
For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS8221677MBS8221677 is an siRNA targeting DNMT3B. Also known as DNMT3B siRNA (Mouse). Reactive in Mouse. Host: Synthetic. siRNA to inhibit DNMT3B expression using RNA interference More details
Product Overview
Online Datasheet in PDFProduct Name
DNMT3B, siRNA
Full Product Name
DNMT3B siRNA (Mouse)
Product Gene Name
DNMT3B sirna
Product Synonym Names
DNA; cytosine-5)-methyltransferase 3B; Dnmt3b; DNA methyltransferase MmuIIIB; DNA MTase MmuIIIB; M.MmuIIIB
Host
Synthetic
Species Reactivity
Mouse
Form/Format
Lyophilized powder
Purity/Purification
> 97%
Specificity
DNMT3B siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Molecular Weight
90,021 Da
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse DNMT3B gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Applications Tested/Suitable for DNMT3B sirna
RNA Interference (RNAi)
Other Notes
Small volumes of DNMT3B sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Additional Details
NCBI/Uniprot data below describe general gene information for DNMT3B. It may not necessarily be applicable to this product.
UniProt Primary Accession #
UniProt Related Accession #
GenBank Nucleotide #
NCBI Official Full Name
DNA (cytosine-5)-methyltransferase 3B isoform 2
NCBI Official Synonym Full Names
DNA methyltransferase 3B
NCBI Official Symbol
Dnmt3b
NCBI Official Synonym Symbols
MmuIIIB
UniProt Protein Name
DNA (cytosine-5)-methyltransferase 3B
UniProt Synonym Protein Names
DNA methyltransferase MmuIIIB; DNA MTase MmuIIIB; M.MmuIIIB
Protein Family
DNA
UniProt Gene Name
Dnmt3b
UniProt Synonym Gene Names
Dnmt3b; DNA MTase MmuIIIB; M.MmuIIIB
UniProt Entry Name
DNM3B_MOUSE
NCBI Protein Information
DNA (cytosine-5)-methyltransferase 3B
NCBI Summary for DNMT3B
This is one of two related genes encoding de novo DNA methyltransferases, which are responsible for the establishment of DNA methylation patterns in embryos. Loss of function of this gene results in severe developmental defects and loss of viability. Mutation of the related gene in humans causes immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome. There is a pseudogene for this gene located adjacent to this gene in the same region of chromosome 2. Alternatively spliced transcript variants encoding multiple isoforms have been observed. [provided by RefSeq, Nov 2012]
Show more UniProt Comments for DNMT3B
DNMT3B: a ubiquitous DNA methyltransferase required for genome wide de novo methylation and essential for development. DNA methylation is coordinated with methylation of histones. Numerous cancer cell lines and primary acute leukemias express aberrant DNMT3B transcripts, especially DNMT3B7. Transfection of DNMT3B7 into 293 cells alters the pattern of genes expressed in the transfected cells. Can interact with DNMT1, which might be a co-operative event during DNA methylation. Methylates CpG sites at a rate slower than DNMT3A and much slower than DNMT1. Interacts with SUV39H1, SETDB1, SUMO1 and UBE2I9. Interacts with DNMT1 and DNMT3A. Mutations in DNMT3B have been shown to cause immunodeficiency-centromeric instability-facial anomalies syndrome (ICF). Six alternatively spliced isoforms of the human protein have been reported. Isoform 1 is expressed in all tissues except brain, skeletal muscle and PBMC, 3 is ubiquitous, 4 is expressed in all tissues except brain, skeletal muscle, lung and prostate and 5 is detectable only in testis and at very low level in brain and prostate. Isoforms 4 and 5 are probably not enzymatically active due to the deletion of two conserved methyltransferase motifs.
Protein type: Amino Acid Metabolism - cysteine and methionine; Methyltransferase, DNA; EC 2.1.1.37; Methyltransferase; Cell development/differentiation
Cellular Component: nucleoplasm; heterochromatin; intracellular membrane-bound organelle; cytoplasm; nuclear heterochromatin; nucleus; chromosome, pericentric region
Molecular Function: transferase activity; DNA (cytosine-5-)-methyltransferase activity; methyltransferase activity; protein binding; DNA binding; unmethylated CpG binding; DNA (cytosine-5-)-methyltransferase activity, acting on CpG substrates; metal ion binding; histone deacetylase binding; chromatin binding; transcription corepressor activity
Biological Process: negative regulation of histone H3-K9 methylation; methylation; genetic imprinting; S-adenosylhomocysteine metabolic process; positive regulation of histone H3-K4 methylation; negative regulation of transcription from RNA polymerase II promoter; cytosine methylation within a CG sequence; protein complex localization; methylation-dependent chromatin silencing; negative regulation of gene expression, epigenetic; DNA methylation; S-adenosylmethioninamine metabolic process; negative regulation of transcription, DNA-dependent; positive regulation of neuron differentiation
Show more Protein type: Amino Acid Metabolism - cysteine and methionine; Methyltransferase, DNA; EC 2.1.1.37; Methyltransferase; Cell development/differentiation
Cellular Component: nucleoplasm; heterochromatin; intracellular membrane-bound organelle; cytoplasm; nuclear heterochromatin; nucleus; chromosome, pericentric region
Molecular Function: transferase activity; DNA (cytosine-5-)-methyltransferase activity; methyltransferase activity; protein binding; DNA binding; unmethylated CpG binding; DNA (cytosine-5-)-methyltransferase activity, acting on CpG substrates; metal ion binding; histone deacetylase binding; chromatin binding; transcription corepressor activity
Biological Process: negative regulation of histone H3-K9 methylation; methylation; genetic imprinting; S-adenosylhomocysteine metabolic process; positive regulation of histone H3-K4 methylation; negative regulation of transcription from RNA polymerase II promoter; cytosine methylation within a CG sequence; protein complex localization; methylation-dependent chromatin silencing; negative regulation of gene expression, epigenetic; DNA methylation; S-adenosylmethioninamine metabolic process; negative regulation of transcription, DNA-dependent; positive regulation of neuron differentiation
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with DNMT3B sirna
| Reference Product | PubMed Publications |
|---|---|
| Dnmt3a sirna | >563 publications with DNMT3B and Dnmt3a |
| Dnmt1 sirna | >552 publications with DNMT3B and Dnmt1 |
| Dnmt3l sirna | >90 publications with DNMT3B and Dnmt3l |
| Hdac1 sirna | >44 publications with DNMT3B and Hdac1 |
| Nanog sirna | >33 publications with DNMT3B and Nanog |
| Hdac2 sirna | >27 publications with DNMT3B and Hdac2 |
| Ezh2 sirna | >22 publications with DNMT3B and Ezh2 |
| Suz12 sirna | >4 publications with DNMT3B and Suz12 |
| Sin3a sirna | >4 publications with DNMT3B and Sin3a |
| Smarca5 sirna | >3 publications with DNMT3B and Smarca5 |
Pathways associated with DNMT3B sirna
| Products by Pathway | Pathway Diagram |
|---|---|
| Cysteine And Methionine Metabolism Pathway antibodies | Cysteine And Methionine Metabolism Pathway Diagram |
| Cysteine And Methionine Metabolism Pathway antibodies | Cysteine And Methionine Metabolism Pathway Diagram |
| DNA Methylation Pathway antibodies | DNA Methylation Pathway Diagram |
| Epigenetic Regulation Of Gene Expression Pathway antibodies | Epigenetic Regulation Of Gene Expression Pathway Diagram |
| Gene Expression Pathway antibodies | Gene Expression Pathway Diagram |
| Glutathione And One Carbon Metabolism Pathway antibodies | Glutathione And One Carbon Metabolism Pathway Diagram |
| Metabolic Pathways antibodies | Metabolic Pathways Diagram |
| Methionine Degradation Pathway antibodies | Methionine Degradation Pathway Diagram |
| Methionine Degradation Pathway antibodies | Methionine Degradation Pathway Diagram |
| MicroRNAs In Cancer Pathway antibodies | MicroRNAs In Cancer Pathway Diagram |
Diseases associated with DNMT3B sirna
| Disease Name | Pubmed Publications |
|---|---|
| Carcinoma Antibodies | >163 publications with DNMT3B and Carcinoma |
| Adenocarcinoma Antibodies | >61 publications with DNMT3B and Adenocarcinoma |
| Immunologic Deficiency Syndromes Antibodies | >47 publications with DNMT3B and Immunologic Deficiency Syndromes |
| Breast Neoplasms Antibodies | >47 publications with DNMT3B and Breast Neoplasms |
| Lung Neoplasms Antibodies | >46 publications with DNMT3B and Lung Neoplasms |
| Carcinoma, Hepatocellular Antibodies | >41 publications with DNMT3B and Carcinoma, Hepatocellular |
| Liver Diseases Antibodies | >40 publications with DNMT3B and Liver Diseases |
| Lung Diseases Antibodies | >33 publications with DNMT3B and Lung Diseases |
| Liver Neoplasms Antibodies | >33 publications with DNMT3B and Liver Neoplasms |
| Neoplasms, Experimental Antibodies | >29 publications with DNMT3B and Neoplasms, Experimental |
Organs/Tissues associated with DNMT3B sirna
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Embryonic Tissue Antibodies | >50 publications with DNMT3B and Embryonic Tissue |


